Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including...
angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 16, 2022 11:01am
$HEM ACP-01 clinical trial scores
$HEM has already announced the results from its 2nd phase CLI trial under the guidance of Hemostemix itself, which has noted healing of ulcers and resolution of the pain of ischemia, which occurred in
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 2:55pm
Hemostemix Inc. Market Graph
Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.28-$0.30. In the last 52 weeks it is $0.13-$0.42.
Fintech Select LTD. Publishes Results for Fiscal Year 2023
posted May 01, 2024 9:00am by
Fintech Select Ltd.
-
|
Under the leadership of Fintech Select's management, the Company achieved a significant milestone in revenue generation, reaching $3,822,182 for fiscal year 2023, compared to $2,587,867 in 2022. Management is confident this 47% increase on a year-over-year basis ...read more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:48pm
Hemostemix Inc. Stock overview
Hemostemix is a Canadian based biotechnology company listed on TSX-V currently sits at $0.30 with a trading volume over $13K.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:34pm
Hemostemix information regarding intellectual property
Hemostemix Inc. recently announced the settlement of all litigation with aspire Health Service Inc., AJIA Global, LLC and Alan Jacobs, Jed Wood, Randi Wood, Blake Wood, Kyle Makofka, Reginald
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:15pm
The Exercise Price option granted by $HEM
According to Hemostemix Inc., all the stock options were granted with an exercise price of $0.17 per common share and have an expiry date of February 28, 2027.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:02pm
The Peer review Articles by Hemostemix
The company has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and
...more
(81)
•••
vinneyquaw2
X
View Profile
View Bullboard History
Comment by
vinneyquaw2
on Jun 15, 2022 11:41am
RE:RE:RE:Still waiting.. When i see volume rising i might hop in
Rambo - pp supposed to close Friday probably with some news about what's going on with HEM - could be good news. Lots of little signs indicating something could be up? Might kick yourself if you
...more
(147)
•••
RamboOO7
X
View Profile
View Bullboard History
Comment by
RamboOO7
on Jun 15, 2022 10:39am
RE:RE:Still waiting.. When i see volume rising i might hop in
Good luck. I am still waiting to jump in. Volume is still too low. Hope i don't miss the boat hahahahaha
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 14, 2022 2:48pm
$HMTXF’s new operations vice president with an spotless resu
Mr. Pete Palvin who recently joined as vice president to the operations department has evaluated the performance of NASA space shuttle ASRM refurbishing reboot system with the application real time
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 14, 2022 1:17pm
$HMTXF reports private placement of 15 million units Hemost
Hemostemix in a recent press release has announced a non-brokered private placement of around 15 million units for its existing shareholders.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 14, 2022 11:12am
$HEM has updated its financial status on TSX-Venture
Hemostemix has updated its financials and announced a non-brokered private placement of up to 15 million units priced in the market.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 14, 2022 10:53am
Hemostemix Inc. Valuation Measures
Hemostemix Inc. is a clinical-stage biotechnology company leading on TSX-V with a market cap of $19.793M.
(42)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Jun 14, 2022 10:35am
More good news!
Great to see the move on the neural cell line! HEM is getting its ducks in a row, the company is ensuring a turn-key operation to present to the market pending Pahse II results!
(36)
•••
GustheGreek
X
View Profile
View Bullboard History
Comment by
GustheGreek
on Jun 14, 2022 10:16am
RE:Still waiting.. When i see volume rising i might hop in
I bought more too... under 30 cents in my opinion, Is a bargain. GLTA!
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 14, 2022 8:22am
New Press Release - Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01
Calgary, Alberta--(Newsfile Corp. - June 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has incorporated PreCerv Inc. ("PreCerv"), as a wholly owned subsidiary. PreCerv will obtain from Hemostemix a global field of use license to...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results